Glytec, the industry leader in glycemic safety, has joined HAPevolve, a subsidiary of The Hospital and HealthSystem Association of Pennsylvania (HAP). This partnership gives HAP member hospitals access to GlytecOne, Glytec’s Intelligent Glycemic Management platform, which combines FDA-cleared insulin dosing support via Glucommander® with clinical data visualization and analytics to help health systems reduce glycemic variability, support safer insulin management, and prepare for CMS glycemic quality measure reporting.

Inpatient glycemic management remains a significant patient safety challenge. Many hospitals still rely on manual protocols, sliding-scale dosing, and unvalidated calculators to manage insulin, a high-alert medication. At the core of GlytecOne is Glucommander, an FDA-cleared Class II Software as a Medical Device that provides algorithm-based IV and subcutaneous insulin dosing recommendations for hospitalized adult and pediatric patients ages 2 and older. Clinicians review and confirm all recommendations. Published evidence has demonstrated that use of Glucommander is associated with a 99.8% reduction in the frequency of severe hypoglycemia compared to paper protocols, up to a 3.2-day reduction in average length of stay, and 90-100% clinician satisfaction across deployed sites.

The platform also includes data insights, which provides current and retrospective population health analytics to help quality and clinical leaders track glycemic program performance, identify trends, and support quality improvement initiatives. Together, Glucommander supports safe, individualized insulin dosing for hospitalized patients, while the data dashboards give leaders visibility into glycemic outcomes across the institution to support ongoing improvement. With CMS now requiring hospitals to measure and report severe hypoglycemia and hyperglycemia as electronic clinical quality measures, this combination helps Pennsylvania hospitals build the infrastructure needed for reliable glycemic safety and accountability.

Glytec has guided safe insulin dosing for millions of patients across 400+ hospitals and health systems nationwide since 2006. Glucommander has been FDA-cleared since 2006 for IV insulin dosing and since 2010 for subcutaneous dosing. The platform integrates with Epic, Oracle Health (Cerner), and Meditech, supporting adoption within existing EHR workflows. Glucommander is an FDA-cleared Class II medical device.  

HAPevolve identifies and creates valuable partnerships with a variety of businesses serving the health care community. By negotiating with its industry and endorsed partners on behalf of the Pennsylvania hospital and health care community at large, HAPevolve can offer members special benefits and discounts on innovative solutions that can save them both time and money.

To explore how Glytec can benefit your organization, contact: Melis Akiz, RVP, Glytec, or Lori Mulholland, director, business development, HAPevolve.